Offer - Urjas Oil for just ₹ 1
Calmstay 0.25 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Based on research, the following side effects have been observed when Calmstay 0.25 Tablet is used -
Severe
Moderate
Mild
Is the use of Calmstay 0.25 Tablet safe for pregnant women?
Calmstay may cause moderate side effects during pregnancy. If you feel its harmful effects, then stop taking this drug immediately, and do not take Calmstay again without your doctor's advice.
Is the use of Calmstay 0.25 Tablet safe during breastfeeding?
Calmstay can cause moderate side effects on breastfeeding women. If you feel its side effects, then stop taking this drug and consult your doctor. Take this medicine again only if your doctor advises to do so.
What is the effect of Calmstay 0.25 Tablet on the Kidneys?
Calmstay may have mild side effects on the kidneys.
What is the effect of Calmstay 0.25 Tablet on the Liver?
Side effects of Calmstay rarely affect the liver.
What is the effect of Calmstay 0.25 Tablet on the Heart?
Using Calmstay does not have any harmful effects on the heart.
Calmstay 0.25 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Calmstay 0.25 Tablet unless your doctor advises you to do so -
Is this Calmstay 0.25 Tablet habit forming or addictive?
Yes, Calmstay 0.25 Tablet can get addictive. Consume it only after doctor's advise.
Is it safe to drive or operate heavy machinery when consuming?
After taking Calmstay 0.25 Tablet, you should not drive or work on any heavy machine, as Calmstay 0.25 Tablet can make you drowsy.
Is it safe?
Yes, but consume Calmstay 0.25 Tablet only on doctor's advice.
Is it able to treat mental disorders?
Yes, taking Calmstay 0.25 Tablet can treat mental disorders.
Interaction between Food and Calmstay 0.25 Tablet
Taking Calmstay 0.25 Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Calmstay 0.25 Tablet
Consult your doctor before consuming alcohol while taking Calmstay 0.25 Tablet as it can have severe side effects.
Yes, Calmstay causes dry mouth. It is a common side effect of it. If you experience excess dry mouth after taking this drug, please consult your doctor and follow his/her instructions.
Yes, Calmstay causes drowsiness, dizziness or sedation. It is one of the most common side effects of this medicine. Do not drive vehicle or operate machinery after taking this medicine.
Yes, Calmstay causes withdrawal symptoms when the drug is discontinued. These withdrawal symptoms can include new or worsening seizures, hallucinating (seeing things or hearing voices that do not exist), changes in behavior, sweating, uncontrollable shaking of a part of your body, stomach or muscle cramps, anxiety, or difficulty falling asleep or staying asleep.
Yes, Calmstay causes testosterone because of its effect on endocrine gland present in the brain.
Calmstay works by relaxing the muscles of the body and suppressing abnormal activity of nerve cells in the brain through an increase in activity of a chemical messenger known as GABA. Thus, providing relief from sleeplessness and anxiety to the patient.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Klonopin (clonazepam)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 418
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 330-332
